SM
Sabby Management Portfolio holdings
AUM
$13M
This Quarter Return
-2.83%
1 Year Return
-26.95%
3 Year Return
-56.43%
5 Year Return
-61.92%
10 Year Return
-71.17%
AUM
$332M
AUM Growth
+$332M
(+20%)
Cap. Flow
+$91.8M
Cap. Flow
% of AUM
27.62%
Top 10 Holdings %
Top 10 Hldgs %
63.42%
Holding
251
New
43
Increased
41
Reduced
62
Closed
33
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$40.6M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$31.8M |
| 3 |
Amgen
AMGN
|
$17.5M |
| 4 |
Eli Lilly
LLY
|
$15.7M |
| 5 |
Bristol-Myers Squibb
BMY
|
$7.73M |
Top Sells
| 1 |
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
|
$12.8M |
| 2 |
SHPG
Shire pic
SHPG
|
$6.04M |
| 3 |
WGBS
WaferGen Bio-systems, Inc.
WGBS
|
$6.03M |
| 4 |
Abbott
ABT
|
$4.77M |
| 5 |
GNVC
GenVec, Inc.
GNVC
|
$4.46M |
Sector Composition
| 1 | Healthcare | 93.08% |
| 2 | Consumer Staples | 0.27% |
| 3 | Technology | 0.16% |
| 4 | Energy | 0% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$61.5B
| $59.7M | 3.47% | 162,517 +86,598 | +114% | +$31.8M |
|
|
2
Sarepta Therapeutics
SRPT
$1.78B
| $55.3M | 3.22% | 2,014,787 +1,478,505 | +276% | +$40.6M |
|
|
3
Amgen
AMGN
$155B
| $37M | 2.15% | 252,795 +119,619 | +90% | +$17.5M |
|
|
4
Bristol-Myers Squibb
BMY
$96B
| $16.9M | 0.98% | 289,183 +132,296 | +84% | +$7.73M |
|
|
5
Eli Lilly
LLY
$657B
| $15.7M | 0.91% | +213,113 | New | +$15.7M |
|
6
Outlook Therapeutics
OTLK
$37.8M
| $6.74M | 0.39% | 2,238,470 -30,115 | -1% | -$90.6K |
|
7
Biogen
BIIB
$19.4B
| $5.67M | 0.33% | +20,000 | New | +$5.67M |
|
|
MTFB
8
DELISTED
Motif Bio plc ADRs
MTFB
| $5.12M | 0.3% | +847,826 | New | +$5.12M |
|
|
ACOR
9
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $4.96M | 0.29% | +263,947 | New | +$4.96M |
|
10
Applied DNA Sciences
APDN
$1.69M
| $3.9M | 0.23% | +2,109,601 | New | +$3.9M |
|
|
STML
11
DELISTED
Stemline Therapeutics, Inc.
STML
| $3.83M | 0.22% | 357,806 +259,756 | +265% | +$2.78M |
|
|
MDCO
12
DELISTED
Medicines Co
MDCO
| $3.82M | 0.22% | 112,392 +98,884 | +732% | +$3.36M |
|
|
LJPC
13
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $3.7M | 0.22% | 210,978 +90,014 | +74% | +$1.58M |
|
14
Puma Biotechnology
PBYI
$254M
| $3.17M | 0.18% | +103,243 | New | +$3.17M |
|
15
Cidara Therapeutics
CDTX
$1.66B
| $3.04M | 0.18% | 292,398 +102,040 | +54% | +$1.06M |
|
16
Tenax Therapeutics
TENX
$27.3M
| $2.96M | 0.17% | 1,516,835 -896,022 | -37% | -$1.75M |
|
17
Indaptus Therapeutics
INDP
$7.19M
| $2.93M | 0.17% | 514,100 +16,094 | +3% | +$91.7K |
|
|
EIGR
18
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $2.8M | 0.16% | 240,541 +9,738 | +4% | +$113K |
|
19
Plus Therapeutics
PSTV
$45.3M
| $2.49M | 0.15% | 1,651,835 -111,011 | -6% | -$168K |
|
20
Theriva Biologics
TOVX
$3.94M
| $2.31M | 0.13% | +3,031,953 | New | +$2.31M |
|
|
ENDP
21
DELISTED
Endo International plc
ENDP
| $2.08M | 0.12% | 126,139 +66,902 | +113% | +$1.1M |
|
22
DURECT Corp
DRRX
$59.6M
| $2.05M | 0.12% | 1,528,516 -271,484 | -15% | -$364K |
|
|
RDHL
23
Redhill Biopharma
RDHL
$3.1M
| $2.01M | 0.12% | 191,785 +127,985 | +201% | +$1.34M |
|
24
Arbutus Biopharma
ABUS
$711M
| $1.94M | 0.11% | 792,617 -85,914 | -10% | -$210K |
|
25
Editas Medicine
EDIT
$231M
| $1.87M | 0.11% | 115,000 -20,000 | -15% | -$325K |
|